Nivolumab | 130 | 97 | 44 | 15 | 9 | 6 | 15 | 316 |
Pembrolizumab | 18 | 9 | 43 | 2 | 2 | 4 | 15 | 93 |
Ipilimumab | 67 | 1 | 0 | 68 | ||||
Nivolumab + Ipilimumab | 16 | 20 | 9 | 11 | 9 | 65 | ||
Atezolizumab | 7 | 12 | 7 | 3 | 15 | 44 | ||
Spartalizumab | 4 | 5 | 2 | 3 | 5 | 19 | ||
Durvalumab | 11 | 4 | 1 | 16 | ||||
Avelumab | 6 | 1 | 1 | 1 | 2 | 3 | 14 | |
Cemiplimab | 8 | 8 | ||||||
Nivolumab + Relatlimab | 4 | 1 | 5 | |||||
235 | 144 | 114 | 37 | 27 | 19 | 72 | 648 |
Nivolumab | 316 | 33 | 10.4 |
Pembrolizumab | 93 | 11 | 11.8 |
Ipilimumab | 68 | 11 | 16.2 |
Nivolumab + Ipilimumab | 65 | 20 | 30.8 |
Atezolizumab | 44 | 3 | 6.8 |
Spartalizumab | 19 | 1 | 5.3 |
Durvalumab | 16 | 2 | 12.5 |
Nivolumab + Relatlimab | 5 | 2 | 40.0 |
648 | 83 | 12.8 |